Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent-based synthesis of high-purity axial chiral indole-naphthalene compounds enables cost reduction in API manufacturing with mild reaction conditions and high enantioselectivity.
Discover how copper-catalyzed synthesis of benzofuro[2,3-b]quinoline derivatives achieves 96% yield at 100°C, reducing production costs and supply chain risks for pharmaceutical manufacturers.
Discover how glucose-based synthesis of 3-trifluoromethyl-1,2,4-triazole eliminates anhydrous/oxygen-free requirements, cuts production costs, and ensures 99% purity for pharmaceutical intermediates.
Discover how this novel chiral catalyst enables 99% ee synthesis with 90% yield, reducing R&D costs and supply chain risks for oncology drug development.
Discover how novel biphenyl-type tridentate ligand ruthenium complexes enable ester-to-alcohol hydrogenation at 60-100°C and 3-10MPa, reducing costs and safety risks for pharma production.
Discover how NHC-catalyzed trifluoromethyl homoisoflavone synthesis reduces production costs, improves yield, and ensures supply chain stability for pharmaceutical intermediates.
Discover how reductive aminocarbonylation with molybdenum carbonyl reduces raw material costs by 30-40% for (hetero)chroman amide synthesis. Scale-ready for API manufacturing.
Solve chiral drug synthesis challenges with metal-free catalysis. Achieve >99% ee, mild conditions, and scalable production for pharmaceutical intermediates. Reduce costs and supply chain risks.
Solve high-cost N-difluoromethylation challenges with this room-temperature, metal-free method. 90% yields, broad substrate tolerance, and no special equipment needed. Scale to 100 MT/yr.
Solve high-cost deuteration challenges with 98% deuterated aldehyde yield. Our CDMO expertise in metal-free catalysis ensures scalable, pure intermediates for drug development.
Solve 5-trifluoromethyl imidazole synthesis challenges with our CDMO's scalable, high-yield process. Reduce costs by 30% and ensure supply chain stability for your API development.
Discover metal-free β-iodonitroalkene synthesis with 80%+ yields. Eliminate oxidant risks & simplify GMP production for API intermediates.
Discover a cost-effective, scalable synthesis method for 3-trifluoromethyl-1,2,4-triazole compounds with high yields. Ideal for pharmaceutical R&D and production.
Solve metal contamination risks in 2-trifluoromethyl quinoline production. Our green, catalyst-free process ensures high purity and scalable manufacturing for drug development.
Eliminate heavy metal catalysts and nitrogen protection in pyrazole synthesis. Scale to 100MT/yr with 99% purity for drug development.
Solve low yield & high cost in fexuprazan intermediate production. New route with >50% yield, 50% cost reduction. Scale to 100MT/yr.
Discover a novel antitumor compound synthesis with 92-99% yield, mild conditions, and strong HONE-1 cytotoxicity. Optimize your drug development supply chain.
Solve 1,2,4-triazole synthesis challenges: 97% yield, no heavy metals, no anhydrous conditions. Reduce R&D costs and supply chain risks for API manufacturing.
Discover efficient chiral indolo-dihydropyridoindole synthesis with 96% yield and 95% ee. Ideal for pharmaceutical R&D and cancer drug development. Scale up with CDMO expertise.
Discover how metal-free diselenomaleimide synthesis at room temperature reduces production costs and supply chain risks for pharmaceutical intermediates. High-yield, scalable solution for R&D and procurement teams.